Skip to content ↓



Download RSS feed: News Articles / In the Media

Displaying 1 - 15 of 23 news clips related to this topic.


Noubar Afeyan ’87, a member of the MIT Corporation, speaks to Guy Raz of NPR’s How I Built This podcast about his journey toward co-founding Moderna and becoming a part of history through the rapid creation and production of vaccines for the Covid-19 pandemic. “The reality is when you have a pandemic and you’re a public company and you have material data, our sense was that we at a high level had to put that [information] out there,” says Afeyan. “One of these things we learned, because none of us had been in this situation before, is that we are going to get criticized no matter what we did. So, we just had to do what we thought was right.”


Nature reporter Eric Bender spotlights MIT startup Kytopen, which has developed a microfluidic platform to create induced pluripotent stem (iPS) cells and other forms of cell therapy. We want to do minimally invasive surgery,” says Kytopen co-founder Prof. Cullen Buie.


Prof. Jonathan Gruber speaks with Margery Eagan and Jared Bowen on Boston Public Radio about the ethics of offering vaccine booster shots in the U.S. when many nations are struggling with vaccine scarcity. “This is really a moment where, going forward, the world has to figure out a more effective strategy,” said Gruber. “We need to think about how we’re going to set up institutions to deal with these kinds of tradeoffs in the future.” 

National Geographic

National Geographic reporter Roxanne Khamsi spotlights how Prof. Richard Braatz is working on developing continuous manufacturing processes that could help boost global vaccine availability. Khamsi notes that one feature Braatz and his colleagues are testing is using “a filter that attaches to the side of their production tanks to continuously extract vaccine material, rather than harvesting it in bulk.”


As part of the Vax India Now event on CNN, Profs. Bruce Walker, Peko Hosoi and Parag Pathak, along with senior research scientist Chris Caplice and MIT Medical Director Cecilia Stuopis, participate in a discussion led by Vijay Joshi, Editor-in-Chief of The Press Trust of India, about what India can learn from America’s experience with vaccine distribution. “It is absolutely [in the U.S.’s] interest to make sure that everybody in India gets vaccinated, that everybody in South America get vaccinated,” says Hosoi. “We really are all in this together.”

The Atlantic

A new study by Prof. Jeffrey Harris finds that the extensive research invested in developing a vaccine for HIV has contributed to the successful development of Covid-19 vaccines, writes Derek Thompson for The Atlantic. Nearly 90 percent of COVID-19 vaccines that made it to clinical trials used technology that “could be traced back to prototypes tested in HIV vaccine trials,” Harris found.

ABC News

Michelle Penn-Marshall, vice president for research at Hampton University, speaks with ABC News reporter Jade Lawson about how Hampton consulted with MIT researchers on the design of a mobile Covid-19 vaccination unit. "MIT was the first school to have a mobile unit. I contacted MIT when I saw that in the news this summer and said, 'Hey, how can we do this?' They took the time and gave me a one-hour briefing on the mobile unit, and also they gave me information regarding testing efficiency," says Penn-Marshall.


"You remember when we go to election polls, the voting booth, during elections, we get a little sticker that says 'I Voted'" says Prof. Sinan Aral of a new study that finds hearing about people who have received the Covid-19 vaccine can increase vaccine acceptance rates. "You should think of this as a very similar type of strategy. The reason we get that sticker that says 'I Voted' is that social proof motivates people to join in. And so if we got a sticker or put out a video or put out a message that said, 'I got vaccinated,' it would have the same effect for the same reasons."

The New Yorker

New Yorker reporter Benjamin Wallace-Wells spotlights new research from the MIT Initiative on the Digital Economy, which shows “just telling people the accurate immunization rates in their country increased, by five per cent, the number who said that they would get the vaccine.”

New York Times

In a letter to the editor that appeared in The New York Times, senior lecturer Jonathan Byrnes advocates for a continuous flow of vaccinations to quickly protect the population against Covid-19. “We need two things: 1) a core of highly experienced supply chain managers supplementing the public health professionals; and 2) a management structure, probably under the Defense Production Act, to coordinate, organize and manage the supply chain,” Byrnes writes.

The Boston Globe

Writing for The Boston Globe, Prof. Ramesh Raskar underscores the importance of ensuring that every American has the opportunity to receive the Covid-19 vaccine without cost or without giving up their privacy. “By effectively communicating the privacy benefits of decentralized data collection and anonymized data reporting, mobile apps might diminish barriers to vaccination that exist due to privacy concerns,” writes Raskar.

Fast Company

Fast Company reporter Adele Peters spotlights Particles for Humanity, an MIT spinoff that is developing a new technology that makes it possible to deliver multiple doses of a vaccine in one shot. “The new technology works like traditional drug delivery,” writes Peters, “but with the addition of tiny time-release capsules filled with antigens, the part of the vaccine that stimulates the immune system so that it can later respond to a virus.”

Freakonomics Radio

On this episode of Freakonomics, Prof. Andrew Lo discusses the economics of drug development. “It’s important that we get the pricing of these vaccines correct so that they provide both a reasonable rate of return to investors who have risked their capital to develop these vaccines, while at the same time making sure that there’s no price gouging going on and that ultimately we provide access to everybody,” says Lo.

The New Yorker

Writing for The New Yorker, Bernard Avishai spotlights Prof. Andrew Lo’s work exploring the need for a revolution in financial engineering to help spur the development of vaccines, and how a vaccine megafund could have assisted in bringing the Covid-19 pandemic under control. “The more I studied this, the more I realized that finance actually plays a huge role in drug development,” says Lo, “in many cases, way too big a role.”

The Washington Post

Writing for The Washington Post, Prof. Robin Wolfe Scheffler underscores the importance of not only pursuing coronavirus vaccine development initiatives, but also “addressing the social and political factors that exacerbate disease and limit the access of many Americans to basic medical care.”